PERJETA (pertzumab) from Roche
Products has had its extension of
indication approved and detailed in
the latest AusPAR addition.
The product is now indicated in
combination with trastuzumab and
chemotherapy for the neoadjuvant
treatment of patients with
inflammatory or locally advanced
HER2 positive breast cancer as part
of a complete treatment regimen.
Visit www.tga.gov.au for details.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Aug 16
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.